Anti-GPR83/ GIR/ GPR72 monoclonal antibody

Anti-GPR83/ GIR/ GPR72 antibody for FACS & in-vivo assay

Target products collectionGo to GPR83/GPR83 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0548-Ab-1/ GM-Tg-hg-MP0548-Ab-2Anti-Human GPR83 monoclonal antibodyHuman
GM-Tg-rg-MP0548-Ab-1/ GM-Tg-rg-MP0548-Ab-2Anti-Rat GPR83 monoclonal antibodyRat
GM-Tg-mg-MP0548-Ab-1/ GM-Tg-mg-MP0548-Ab-2Anti-Mouse GPR83 monoclonal antibodyMouse
GM-Tg-cynog-MP0548-Ab-1/ GM-Tg-cynog-MP0548-Ab-2Anti-Cynomolgus/ Rhesus macaque GPR83 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0548-Ab-1/ GM-Tg-felg-MP0548-Ab-2Anti-Feline GPR83 monoclonal antibodyFeline
GM-Tg-cang-MP0548-Ab-1/ GM-Tg-cang-MP0548-Ab-2Anti-Canine GPR83 monoclonal antibodyCanine
GM-Tg-bovg-MP0548-Ab-1/ GM-Tg-bovg-MP0548-Ab-2Anti-Bovine GPR83 monoclonal antibodyBovine
GM-Tg-equg-MP0548-Ab-1/ GM-Tg-equg-MP0548-Ab-2Anti-Equine GPR83 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0548-Ab-1/ GM-Tg-hg-MP0548-Ab-2; GM-Tg-rg-MP0548-Ab-1/ GM-Tg-rg-MP0548-Ab-2;
GM-Tg-mg-MP0548-Ab-1/ GM-Tg-mg-MP0548-Ab-2; GM-Tg-cynog-MP0548-Ab-1/ GM-Tg-cynog-MP0548-Ab-2;
GM-Tg-felg-MP0548-Ab-1/ GM-Tg-felg-MP0548-Ab-2; GM-Tg-cang-MP0548-Ab-1/ GM-Tg-cang-MP0548-Ab-2;
GM-Tg-bovg-MP0548-Ab-1/ GM-Tg-bovg-MP0548-Ab-2; GM-Tg-equg-MP0548-Ab-1/ GM-Tg-equg-MP0548-Ab-2
Products NameAnti-GPR83 monoclonal antibody
Formatmab
Target NameGPR83
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-GPR83 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species GPR83/ GIR/ GPR72 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorpGMLPm004256mouse Gpr83 Lentivirus plasmid
    ORF Viral VectorvGMLPm004256mouse Gpr83 Lentivirus particle


    Target information

    Target IDGM-MP0548
    Target NameGPR83
    Gene ID10888,14608,140595,697439,403699,101087170,104968467,100060898
    Gene Symbol and SynonymsGIR,GPR72,GPR83,RP105,RP39,RP82
    Uniprot AccessionQ9NYM4,Q8VHD7,Q9TTQ9
    Uniprot Entry NameGPR83_HUMAN,Q8VHD7_RAT,GPR83_CANLF
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000123901
    Target ClassificationGPCR

    The target: GPR83, gene name: GPR83, also named as GIR, GPR72. Predicted to enable neuropeptide receptor activity. Predicted to be involved in neuropeptide signaling pathway. Predicted to act upstream of or within response to glucocorticoid. Located in cilium. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.